ivermectin in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Krolewiecki, 2020 0.49 [0.01; 26.05]
0.32 [0.10 ; 1.07 ] I-TECH (Lim), 2022, Krolewiecki, 2020 2 0% 535 moderate not evaluable deathsdetailed results I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
0.26 [0.09 ; 0.75 ] I-TECH (Lim), 2022, Kirti, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 4 0% 1,010 moderate not evaluable clinical deteriorationdetailed results I-TECH (Lim), 2022 1.25 [0.87; 1.80]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
0.77 [0.28 ; 2.12 ] I-TECH (Lim), 2022, NCT04523831 (Mahmud), 2020 2 87% 853 moderate not evaluable clinical improvementdetailed results NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.89 [1.06 ; 3.38 ] NCT04523831 (Mahmud), 2020 1 0% 400 NA not evaluable clinical improvement (7-day)detailed results Kirti, 2021 0.90 [0.77; 1.06]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
1.28 [0.61 ; 2.70 ] Kirti, 2021, NCT04523831 (Mahmud), 2020 2 91% 475 moderate not evaluable clinical improvement (time to event analysis only)detailed results NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.89 [1.06 ; 3.38 ] NCT04523831 (Mahmud), 2020 1 0% 400 NA not evaluable hospital dischargedetailed results Kirti, 2021 1.20 [0.73; 1.98]
1.20 [0.73 ; 1.98 ] Kirti, 2021 1 0% 112 NA not evaluable mechanical ventilationdetailed results I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Kirti, 2021 0.20 [0.00; 8.69]
0.39 [0.13 ; 1.16 ] I-TECH (Lim), 2022, Kirti, 2021 2 0% 602 moderate not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
0.92 [0.77 ; 1.09 ] Chaccour, 2020 1 0% 24 NA not evaluable viral clearance by day 7detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
0.91 [0.77 ; 1.08 ] Chaccour, 2020, Kirti, 2021 2 0% 136 low not evaluable ICU admissiondetailed results I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Kirti, 2021 0.90 [0.30; 2.70]
0.84 [0.39 ; 1.78 ] I-TECH (Lim), 2022, Kirti, 2021 2 0% 602 moderate not evaluable serious adverse eventsdetailed results Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
2.14 [0.21 ; 21.56 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 2 0% 408 moderate not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
1.97 [0.55 ; 7.04 ] Chaccour, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 3 36% 432 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 15:43 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 684,886
- roots T: 290
